Background. Glioma-related immunosuppression is well documented; however, the mechanisms of suppression are not fully understood. Here we explore a role for glioma extracellular vesicles (EVs) as a means of immune modulation.
High-grade gliomas (HGGs) are devastating and universally fatal cancers with few treatment options. Traditional therapies marginally extend survival and exhibit minimal success in preventing disease progression. 1, 2 Newer targeted therapies kill glioma cells in a more localized fashion; however, their clinical success has also been limited. 3 -6 Thus, the treatments available are often palliative rather than curative. Current clinical trials investigate the potential induction of antitumor immunity to selectively destroy infiltrating glioma while sparing healthy brain tissue. 7 -9 A better understanding of the convoluted interface between gliomas and the immune system may help overcome tumor-induced suppression. HGGs develop multiple layers of immune evasion and suppression throughout their natural history. Induction of regulatory T cell (Treg) phenotypes and myeloid-derived suppressor cells and absence of danger signals are a few adaptations utilized by gliomas to generate a tumor-tolerant environment. 10 -12 Recent literature implicates extracellular vesicles (EVs), including exosomes and microvesicles, for modulating the tumor microenvironment. EVs resemble small cellular surrogates that act locally and systemically to transfer relatively large amounts of material in discrete packages. When released from a tumor, they aid in tumor progression by remolding the extracellular matrix, inducing angiogenesis, and promoting immune tolerance. 13 -17 EVs in the tumor environment contain a variety of immune-modulating capacities, but the processes of immune cell alteration and tumor tolerance produced by EVs are poorly understood. Tumor-derived EVs are promising candidates for targeting constraint of glioma progression and facilitating effective immune strategies. 18, 19 Previous work revealed a direct correlation between tumor grade and EV release, indicating that more aggressive tumors release more EVs. 20 -22 The highly malignant nature of gliomas and the concentrations of EVs found in circulation of patients with other tumor types 20, 23, 24 suggest a prominent role of EVs in promoting tumor progression and evading immune surveillance. Specific phenotypic changes, differential effects of concentration, and reversibility of damage to immune cells by EVs have yet to be elucidated in gliomas. Understanding the consequences of tumor-derived EVs on immune modulation is necessary for successful glioma immunotherapy. Here we demonstrate that different concentrations of glioma-derived EVs have differential effects on the cytokine output, intracellular signaling pathways, activation status, and migratory capabilities of healthy PBMCs/T cells, which are likely relevant considerations in terms of peripheral circulation and the localized tumor microenvironment.
Materials and Methods

Cell Lines
UPN933 is a grade III anaplastic oligodendroglioma cell line obtained from a tumor resected at the Children's Hospital Colorado on a study approved by the Colorado Combined Institutional Review Board (COMIRB # 95-100). E3-2 and E6-5 are grade IV glioblastoma (GBM) lines obtained from patients undergoing surgery for intracranial tumors at the University of Colorado Hospital who had consented to COMIRB protocol #13-3007. Tumor cells were dissociated and grown under stem cell-like conditions in supplemented Neurobasal A (NBA) medium (Invitrogen Technologies) as described (see also Supplementary material, Methods). 25 
Patient Plasma Collection; Healthy Donor Peripheral Blood Mononuclear Cells
Blood was collected in EDTA tubes from patients undergoing surgery for intracranial tumors under COMIRB protocol #13-3007, as well as from healthy donors. Histological examination confirmed GBM diagnosis in samples used in study. Blood was immediately processed by centrifugation to isolate plasma, which was then stored at 2808C. Specimen collection from both patients and healthy donors followed informed written consent. Healthy donor PBMCs and Jurkat cells were prepared as described (see also Supplementary material, Methods). 26 
Extracellular Vesicle Purification
Extracellular vesicle (EV) purifications from cell culture media and patient plasma were conducted as described (see also Supplementary material, Methods). 27 Proteomic and Western blot characterizations and NanoSight measurements were performed as described 27 (see also Supplementary material, Methods).
Functional Assays
Healthy donor PBMCs were cultured at 1 × 10 6 cells in a 24-well plate with 1 mL of medium. Mitogenic stimulation was conducted with 5 mg/mL phytohemagglutinin (PHA, Sigma), along with varying EV concentrations. Cells were incubated for 24 or 72 hours. We assessed proliferation via [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] assay according to manufacturer's protocol (Promega). Values are average-fold change compared with the control group. Cytokine concentrations in culture media were quantified using ELISAs (R & D Systems), and all groups were run in triplicate.
Cell migration was measured in Boyden chambers using permeable cell culture inserts (8 mm pore size, Corning) in a 24-well plate. PBMCs were plated in the top chamber in 300 mL of media without fetal bovine serum (FBS)+/-PHA. 500 mL media + 10% FBS and varying EV concentrations were plated in the bottom chamber; and cells migrated for 24 hours. We wiped nonmigratory cells from the top chamber, and cells on the bottom were counted using a microscope at 40X magnification. Values were defined as average cell number from 3 random microscope fields (+SEM) for each treatment.
To assess the re-stimulation capacity of EV-treated PBMCs (+PHA), cells were challenged with 2 mg/mL tetanus toxin (Astarte Biologics) in some experiments. In other work, cells were removed from EV-containing media by centrifugation, resuspended in new media (with no tumor EVs), and utilized in a modified mixed lymphocyte reaction using unrelated healthy donors' PBMCs. Cells were cultured in triplicate with 200 mL of media in a 96-well plate for 72 hours. Proliferation and ELISA assays were conducted upon completion of incubation, as described above.
Phospho-Kinase and Cytokine Arrays
Phospho-kinase and Cytokine Panel A Proteome Profiler antibody arrays (R&D Systems) were performed according to manufacturer's protocols. After incubation with PHA and EVs, T cells were negatively selected from the PBMC population using Pan T Cell isolation kits (Miltenyi Biotec) prior to lysis. Cell lysates and culture media were incubated with appropriate arrays along with biotinylated detection antibodies. Streptavidin-HRP and chemiluminescent reagents were used to quantify relative protein concentrations. Chemiluminescence was detected using a FluorChemQ developer and quantified with AlphaView software (Protein Simple). Background was subtracted from each membrane, and average luminosity from duplicate spots was compared between treatment groups. Pathway/functional analysis predictions were based on Ingenuity Pathway Analysis (IPA; Ingenuity Systems/QIAGEN). Significance of predicted functional pathways was determined by the strength of probability that the protein changes between groups would produce such effects, based on literature documentation in the IPA database.
Flow Cytometry
For EV binding/incorporation assays, glioma EVs were labeled with 1,1 ′ -dioctadecyl-3,3,3 ′ ,3 ′ -tetramethylindodicarbocyanine perchlorate (DiD), as described, 28 and EVs were incubated with PBMCs at 100 or 500 mg/mL for 1 or 4 hours. Dynasore (Sigma) was used to inhibit EV uptake as described. 29 Flow cytometric analysis was conducted as described. 28 For immune parameters after incubation with PHA and EVs, PBMCs were resuspended at 1× 10 6 cells and incubated with viability dye eFluor 780 followed by Fc Receptor Binding Inhibitor (eBioscience). Cells were then placed in staining buffer (PBS+2% FBS) and stained with appropriate fluorochromeconjugated antibodies for 45 minutes. Different groups of cells were handled as follows: cells were fixed/permeabilized Hellwinkel et al.: Glioma exosomes induce immune tolerance using FoxP3/Transcription Factor Staining Buffer Set (eBioscience) for 45 minutes prior to antibody incubation in staining buffer for 45 minutes. Prior to intracellular cytokine detection, protein transport inhibitor cocktail (eBioscience) was added to the culture for the last 16 hours of incubation. All experiments were analyzed on a BD LSRII flow cytometer (BD Biosciences) using FlowJo software (TreeStar). APC conjugated anti-CD4 and PE conjugated anti-CD8 antibodies were from Novus Biologicals. Fluorescein isothiocyanate (FITC)-conjugated anti-interferon gamma (IFNg), FITC conjugated anti-FoxP3, PerCP-eFluor 710 conjugated anti-CD25, PE-Cy7 conjugated anti-CD69, and Alexa Fluor700 conjugated anti-CD3 antibodies were from eBioscience.
Statistics
All data shown are represented as mean+ SEM. The fold changes shown represent the percentage difference between specified groups. Student' t test was used to determine differences between variables, with P, .05 considered significant. From EV proteomic analysis (Redzic et al, manuscript in preparation), we identified relevant pathways (and protein members) for ensuing functional studies using the FunRich Functional Enrichment Analysis Tool 30 (Supplementary material, Table S1 ).
Results
Characterization of UPN933 Extracellular Vesicles
Glioma Extracellular Vesicles Bind and Internalize into Peripheral Blood Mononuclear Cells
We tested the binding and internalization of glioma EVs into PBMCs using DiD-labeled 933 and E3-2 EVs in FACS analyses (Supplementary material, Fig. S2 ). Uptake increased with time and dose and was blocked by the dynamin inhibitor Dynasore (which prevents clathrin-dependent endocytosis).
Extracellular Vesicular Modulation of Cytokine Release is Concentration Dependent
To explore the immunomodulatory effects of tumor-derived EVs at various concentrations, we incubated Jurkat cells with PHA and increasing concentrations of UPN933 EVs for 24 hours. Media IL-2 concentrations increased from PHA-stimulated cells with no significant effect of EV treatment up to 100 mg/mL (Fig. 1A) . However, EV concentrations .100 mg/mL resulted in a significant decrease in IL-2 release up to the highest concentration tested. These data display a tipping point at which tumorderived EVs influence Jurkat cell IL-2 release, which reflects cellular activation capacity. To assess cellular changes on both sides of this tipping point, we designated 100 mg/mL and 2000 mg/mL EVs as low and high concentrations for the remaining studies. To confirm that high EV concentrations were not toxic to immune cells, we repeated the study with low and high EV concentrations (72 h incubation) using healthy donor PBMCs. IFNg release revealed a similar profile to that of IL-2 in the previous study, with higher concentration of EVs significantly attenuating IFNg release (Fig. 1B) . Low EV concentration induced similar IFNg output compared with PHA-stimulated cells and did not ablate cytokine release, unlike high EV concentrations. Surprisingly, EV treatment sensitized proliferation in a dose-dependent manner (Fig. 1C) . Incubation with high and low EV concentrations along with PHA induced greater proliferation than PBMCs stimulated with PHA alone. These data indicate that tumor-derived EVs are not lethal to naïve PBMCs and that relatively large EV doses mitigate mitogen-driven IFNg release while promoting proliferation.
Intracellular Signaling and Cytokine Output Reveal Selective T Cell Dysfunction at High and Low Tumor EV Concentrations
Enhanced proliferation and decreased IFNg output after exposure to high EV concentrations imply eccentricity of signaling cascades within EV-treated cells. We assessed glioma EVinduced T cell alterations via phospho-kinase and cytokine arrays to detect relative protein concentrations between differentially stimulated groups. PBMCs were incubated for 24 hours with PHA alone or PHA+low or high EV concentrations; T cells were purified and lysed for array exposure and quantification (Fig. 2) . Treated PBMC media were used for cytokine analysis (below). Treatment of bulk PBMCs rather than purified T cells alone reflects the in vivo scenario in which lymphocytes besides T cells may impact T cell responses. Differential protein phosphorylation implicated in a variety of signaling cascades revealed EV-induced changes compared with PHA-stimulated cells (Supplementary material, Table S2 ). IPA algorithms predicted significant downstream effects based on phosphorylation status changes. These include induction of pathways implicated in cellular proliferation, development, and migration of T cells after PBMC incubation with low EV concentrations (Fig. 2) . These predictions suggest exacerbation of overall activation and functionality of T cells exposed to low concentrations of tumor-derived EV+PHA compared with PHA alone. Of 45 proteins analyzed, 35 exhibited .10% increase in phosphorylation after exposure to low EV concentrations (Supplementary material, Table S2 ). Incubation with high EV concentrations, however, does not induce a similar activation profile. The primary functional pathways predicted to increase over PHA-stimulated cells involved proliferation, but no other pathways were predicted to change significantly (Fig. 2) .
EVs induce differential T cell stimulus and cytokine release in a concentration-dependent fashion, with the associated cytokine profiles having potential downstream consequences (Supplementary material, Table S3 , Fig. 3A) . Predicted functional Hellwinkel et al.: Glioma exosomes induce immune tolerance changes based on cytokine output indicate enhanced functionality of PBMCs exposed to low EV concentrations for 72 hours (Fig. 3B) . The magnitudes and types of cytokines released suggest induced activation, migration, and differentiation of cells in response to low tumor EV concentrations. Exposure to high EV concentrations results in reduced levels of many mitogeninduced signaling molecules. Compared with PHA-stimulated cells, the functional consequences of the cytokine milieu produced by this environment suggest decreases in migratory and activation capabilities (Fig. 3B) . Nonetheless, lymphocyte proliferation is still predicted to increase with higher EV concentrations, supporting the unexpected proliferation data (Fig. 1C) . The overall predictive IPA analyses, which are based on relative protein changes, reveal a severe functional deficit induced by exposure to high EV concentrations even in the presence of mitogenic stimulation. Low EV concentrations appear to enhance PBMC functions, but to better understand specific phenotypic changes and physiological consequences of altered protein expression, we directly tested activation makers and functional capabilities in remaining studies.
High Tumor-derived EV Concentrations Decrease PBMC/T Cell Activation
Following incubation of PBMCs with PHA and EVs, we probed cells with anti-CD69 and anti-IFNg antibodies to assess changes in activation status by fluorescence-activated cell sorting (FACS). We analyzed CD3+/CD4+ cells selected from the lymphocyte gate. Mitogenic stimulation reliably elevated expression of CD69 and intracellular IFNg after 72 hours of incubation (P ¼ .02) (Fig. 4A and  B) . Co-incubation with low EV concentrations did not attenuate either parameter but instead trended towards exacerbation of expression, as IPA predicted in the previous study. PBMC incubation with a high concentration of UPN933 EVs constrains the effects of mitogenic stimulation effects on CD69 and IFNg expression but remained higher than control levels (P ¼ .02). Repeating the incubation with GBM patient plasma-derived EVs demonstrates a very similar trend. High EV concentrations decrease CD69 and IFNg expression, and low concentrations have little effect compared with PHA stimulation (Fig. 4B) . It is important to note that patient plasma EVs contain tumor-derived EVs as well as healthy (normal cell) EVs participating in normal functions, whereas the UPN933 EVs from cell culture are all tumor derived. Thus, variation between samples is expected due to nonselective purification of EVs, but the expression patterns of CD69 and IFNg nearly mimic those driven by pure tumor EVs (Fig. 4) .
Tumor-derived EVs Act as Chemorepellents for Activated PBMCs
Array studies implied aberrations of migratory pathways within EV-treated PBMCs, and flow cytometry studies revealed differential expression of activation markers. To confirm that these molecular markers were indicative of cellular functionality, we performed migration assays. Briefly, PBMCs (+PHA) were plated in the top of a Boyden chamber, and UPN933 and GBM patient EVs were plated in the bottom well at 100 mg/mL and 2000 mg/mL (with FBS) for 24 hours. PHA stimulation expectedly 
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enhanced migration 60 percent (P , .001) (Fig. 5) . The presence of low concentration of EVs as putative attractants significantly attenuated PBMC migration (P ¼ .002) but remained greater than control levels of spontaneous migration (P ¼ .03). The presence of high concentrations of glioma EVs as attractants significantly reduced migration compared with low EV concentration (P ¼ .02) and was the same as control levels (P ¼ .71). Overall trends and significance between groups were nearly identical between UPN933 and GBM 8 -5 patient EVs (Fig. 5 , left and right panels). Although signaling cascades in the array study suggested enhanced functionality of PBMCs in the presence of low concentrations of tumor-derived EVs, migration data reveal an inverse relationship between EV concentration and PBMC migration.
PBMCs Remain Suppressed in the Presence of EVs
The studies above suggest an EV-induced deficit in PBMC activation pathways and functionality. We further examined tumor EV effects on other forms of T cell stimulation and asked if the EV-induced impairment was reversible. Supplementary material, Fig S3A reveals that tumor EVs reduce PBMC release of IFNg when the cells are stimulated with PHA followed by further stimulation with tetanus toxin, while the recall antigen alone combined with PHA almost doubles IFNg release. However, EVs continue to promote PBMC proliferation at dramatic levels in the presence of tetanus toxin (Supplementary material, Fig  S3B) . 31 Thus, the ratio of cell number to IFNg release is greatly skewed between the control and EV-treated cells.
We also incubated PBMCs with PHA+EVs at the 2 concentrations and either washed out the EVs from the cells or allowed the EVs to remain in the culture. We then incubated the PBMCs with unrelated healthy donor PBMCs in the form of a mixed lymphocyte reaction (MLR, Fig 6A) . Cells in the MLR release prodigious amounts of IFNg in the absence of EVs (albeit less when stimulated with PHA, Fig 6B) . The continued presence of EVs at both low and high concentrations significantly reduced cytokine release (P , .001), but removal of the EVs prior to MLR Hellwinkel et al.: Glioma exosomes induce immune tolerance allowed for a significant increase in IFNg output (P ¼ .001). These data indicate the importance of continual EV exposure to PBMC inhibition but also suggest that their removal may permit immune stimulation.
Discussion
Our studies assessed the consequences of exposing naïve PBMCs to glioma-derived EVs to better understand EV roles in glioma-induced immune tolerance. There are numerous reports of tumor-derived EV immune suppression. 32 -34 While this is likely true in gliomas as well, 35 there are few reports of glioma EV-mediated immune dysfunction. 18 The latter publication involved in vivo (murine) EV treatments and is difficult to compare directly to our work here. Our current studies used relatively high EV concentrations compared with most. We believe that our EV concentrations represent reasonable amounts in blood (at the low end, 100 mg/mL) and possibly in the tumor microenvironment (high end, 2000 mg/mL) based on values in the literature for blood EVs from patients with numerous tumor types (Supplementary material, Table S4 ) and using a hypothetical tumor model (see Supplemental material and Methods for calculations).
Other than our own work, 27 we found only one other publication with similar EV concentrations. 36 There, the authors found that healthy donor plasma EVs could suppress activation-driven CD4+ T-cell proliferation by FasL-dependent mechanisms with EV concentrations as high as 500 mg/mL. In our hands, however, UPN933 EVs (and cells) did not appear to express high FasL levels since we could not detect it in Western blots (Supplementary material, Fig. S1C ).
As we exposed Jurkat cells to increasing concentrations of glioma EVs, we found a tipping point at which EVs inhibited mitogen-induced IL-2 release. We saw similar suppression of IFNg output from PHA-activated PBMCs incubated with high EV concentrations, suggesting that the local tumor EV concentration impacts PBMC activation status. Cell-wide protein phosphorylation assessment, cytokine release, and FACS for activation markers further supported this. Low EV concentrations sensitized T cell signaling, resulting in enhanced signaling cascades related to proliferation, differentiation, and migration. High EV concentrations did not significantly alter intracellular phosphorylation of these same pathways but selectively enhanced proliferation cascades. Cytokine release revealed a similar alteration in predicted functional capacities at low EV concentrations but demonstrated a more immunosuppressive cytokine output at high Hellwinkel et al.: Glioma exosomes induce immune tolerance EV concentrations. T cells were purified to study intracellular signaling changes, but the cytokine output was from total PBMCs as we presume this creates a more realistic image of what occurs in vivo where PBMCs work in concert. FACS for intracellular T cell IFNg after treatment with high or low EV concentrations paralleled cytokine array data, confirming the T cell contribution to that readout. The changes in activation marker status (CD69 and IFNg) also confirmed the predictions from the array data, and we obtained very similar expression profiles using GBM patient-derived EVs. Note that, in our hands, EV exposure did not induce a Treg phenotype (Supplementary material, Fig. S2 ). Treg production is a known feature of HGGs via tumor cytokine release or from other immunosuppressive cell types, 10, 37, 38 and EVs from other tumors induce Tregs. 39 Our data here do not support Treg induction, but this is admittedly is a limited evaluation.
We have previously 27 shown that tumor EVs effectively drive brain tumor cell migration. In contrast, following functional analysis prediction based on cytokine release, PMBCs exposed to high glioma EV concentrations demonstrated reduced migration in Boyden chamber assays with EVs from both UPN933 and patient plasma. This suggests tumor-derived EVs attract infiltrating cancer cells while essentially repelling immune cells along the course. Tumor-derived EVs can remodel the extracellular matrix (driving stromal cells to do the same), allowing tumor cell migration, 40, 41 and this is likely true for glioma EVs and subsequent glioma invasion. 42 However, tumor-EV effects on PBMC migration appear unstudied, and the dichotomy of response (attractive for tumor cells, preventative for lymphocytes) may be a novel form of immune suppression, particularly in light of the differential activation status of the PBMCs/T cells. EV-induced migratory suppression before other functions at low EV concentrations may be critical for a growing tumor, as it releases greater amounts of EVs to evade immune detection before actively suppressing other T cell functions. These consequences may be pertinent to autologous T cell transfer and vaccine-related studies, as migratory blocking could prevent even the best-educated cells from extravasation into the tumor. There are implications for T cell-based immunotherapies such as autologous T-cell transfer, in which patient plasma/sera are frequently used as part of the cell culture protocol. 43, 44 Tumor EVs in these biofluids may unwittingly inhibit T-cell activity ex vivo.
Since EVs are produced from all cell types and are utilized to maintain homeostasis, prevention of release may not be feasible. However, extracorporeal hemofiltration is proposed as a means of reducing tumor EV burden in blood 45 and may improve PBMC responsiveness. Additionally, some of the signaling pathways affected (CD3/ZAP70, LCK, PLCG1, RAS/RAF, AP-1, NFAT/NFkB) 46 suggest that if removal of EVs is not possible, stimulation of such pathways may resurrect T cell immune responses. Finally, outright blocking of EV/recipient cell interactions (eg, with heparin or other highly charged macromolecules 47 ) may also be a viable means of diminishing tumor EV effects.
Despite EV-induced suppression, PBMCs can still produce immune responses when challenged in an environment with EVs removed. PBMCs with previous EV exposure challenged in MLR with the EVs washed out reveal a sensitization in IFNg release. However, if EVs remain present during challenge, IFNg release is significantly reduced. Thus, continued EV presence is necessary to maintain suppression. The ubiquitous presence of EVs in the tumor microenvironment may be a major obstacle preventing the full potential of immunotherapy. Our data reveal that EV-treated PBMCs are suppressed, but perhaps not permanently, and removal of EVs from the environment may be necessary to produce an efficient immune response. Our additional data imply that stimulation of other pathways may impact lymphocyte activation. 46 The quantity of EVs in the tumor microenvironment remains an issue. We chose our EV concentrations to potentially mimic tumor EV levels in blood versus the tumor microenvironment (Supplementary material, Table S4 ; Supplemental material, Methods). Thus, we believe our EV concentrations utilized are not unrealistic physiologically but may actually be low, relative to the tumor microenvironment. Further work in this area is needed.
Clearly, glioma-derived EVs impact recipient immune cells, but the nature of those interactions and the molecular drivers remain unknown. Better characterization of glioma-derived EV contents and mechanisms of immune cell interactions are necessary to reverse EV-induced dysfunction; many of these putative pathways are noted in Supplementary material, Table S1 . Further exploration of induced signaling pathways in recipient , and IFNg release was measured by ELISA; a second PBMC group was PHA-treated and then utilized in MLR, with IFNg release measured; a third group was PHA-stimulated and treated to low and high EV concentrations followed by MLR (with EVs remaining during the MLR), and IFNg release measured; a fourth group was treated as above, but EVs were washed out prior to MLR/ IFNg release. (B) IFNg concentration of media from PBMCs treated as described in (A). Background release of IFNg without MLR stimulation was 0.158 ng/mL (Fig. 1B) . *P , .05, **P , .01, ***P , .001 compared to No Tx control.
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Conclusion
Our work here suggests that high glioma-derived EV concentrations can deactivate T cells and hinder lymphocyte migration; the more EVs a tumor produces or the closer a T cell gets to a tumor EV gradient, the greater suppression likely exists. Understanding the intracellular/extracellular pathways implicated in alteration from active to suppressed (and relatively immobile) is essential for developing effective treatments aimed to restore function in immune-suppressed cells.
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